BPC-157 peptide and its effects
BPC-157 is a pentadecapeptide with sequence GEPPPGKPADDAGLV, (also known as Body Protection Compound 157, bepecin, or PL 14736), originally isolated from gastric juice showing regenerative properties across numerous animal models.
BPC-157 has gained significant attention in experimental pharmacology and sports medicine circles for its potent tissue-regenerative and anti-inflammatory properties observed in a few preclinical studies.
BPC-157 activates several overlapping pathways, including VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis, promoting angiogenesis, fibroblast activity, and neuromuscular stabilization. It also engages ERK1/2 signaling, facilitates endothelial and muscle repair, and exerts anti-inflammatory effects, particularly in poorly vascularized tissues such as tendons and myotendinous junctions. BPC-157 promotes tissue regeneration, cytoprotection, and neuromodulation, and accelerates tendon and ligament repair through enhanced fibroblast proliferation and collagen synthesis, primarily via focal adhesion kinase (FAK)-paxillin signaling pathways.
BPC-157 increases growth hormone receptor (GHR) expression in fibroblasts, augmenting the anabolic healing response, thus improving tendon structure and biomechanical function, even in conditions impaired by corticosteroids or limited vascular supply.
In cellular and animal models, BPC-157 upregulates vascular endothelial growth factor (VEGF) receptor expression and activates the eNOS/Akt pathway. This promotes the formation of new blood vessels, accelerating nutrient flow to damaged tissue.
Research in rodent models revealed accelerated recovery rates for transected tendons, torn ligaments, muscle injuries, and bone fractures by promoting fibroblast proliferation and collagen synthesis and displays protective effects against NSAID-induced gut lesions, gastric ulcers, and inflammatory bowel conditions by modulating inflammatory cytokines like NF-κB and TNF-α.
However, according to McGuire et al., there have been limited in vivo clinical trials conducted to demonstrate the effectiveness of BPC-157 usage in humans; there have only been three published studies so far.
BPC-157 is stable at room temperature and bioavailable in rodent models when administered IM or IV. The peptide is stable in human gastric juice, remaining intact for more than 24 hours, which supports its therapeutic effectiveness when administered orally.
Possible side effects: Proposed possible unwanted effects include pathologic angiogenesis, toxic metabolite formation, and overproduction of nitric oxide.
As of 2022, the peptide has been banned by the World Anti-Doping Agency under the S0 category of non-exempt substances. BPC-157 is detected in urine using a weak cation exchange solid phase extraction and was found to be stable in urine for 4 days.
Human Clinical Data is extremely limited, and almost all published literature relies on in vitro cell assays and animal (rodent) models.
BPC-157 is not an FDA-approved drug or dietary supplement for human use.
References
"2022 Prohibited List: Substances and Methods Prohibited at ALL Times (in- And OUT-Of-Competition)" (PDF). World Anti-Doping Agency. WADA. Retrieved 21 February 2022.
"World anti-Doping CODE International Standard Prohibited LIST 2025" (PDF). World Anti-Doping Agency. WADA. Retrieved 17 November 2025.
BPC-157
Cerovecki T, Bojanic I, Brcic L, Radic B, Vukoja I, Seiwerth S, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28:1155–61. [PubMed]
Cox HD, Miller GD, Eichner D (October 2017). "Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H". Drug Testing and Analysis. 9 (10): 1490–1498. [PubMed]
Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377:153–9. [PubMed]
He L, Feng D, Guo H, Zhou Y, Li Z, Zhang K, et al. (2022-12-14). "Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs". Frontiers in Pharmacology. 13 1026182. Frontiers Media SA. [PMC]
Jozwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and possible medical application of the BPC 157 Peptide—Literature and patent review. Pharmaceuticals. 2025;18:185. [PMC] [PubMed]
Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to‐bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24:982–9. [PubMed]
Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF, et al. (January 2026). "Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians". The American Journal of Sports Medicine. 54 (1): 223–229. [PubMed]
McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025 Dec;18(12):611-619. [PMC]
Mendias CL, Awan TM (April 2026). "Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance". Sports Medicine. Auckland, N.Z. [PubMed]
Seiwerth S, Milavic M, Vukojevic J, Gojkovic S, Krezic I, Vuletic LB, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol. 2021;12:627533. [PMC] [PubMed]